Still Have Questions?

If you did not find an answer to your question, please contact us to speak with an expert:

Business days: 8 AM - 4 PM ET

    Training Video: Handling iCell Cardiomyocytes

    This training video shows the proper techniques for storing, thawing, seeding, plating and maintaining iCell® Cardiomyocytes for use in your intended assays. Please contact Cellular Dynamics Technical Support for additional questions about these cells, and their proper handling and use in your assay application.

    (Oct 21, 2011)

    Stem Cells from Blood Cells

    Jeff Angileri, WMSN Fox 47, Madison, WI

    News coverage from WMSN Fox 47 in Madison, WI of Cellular Dynamics stem cell technology and applications of adult-derived pluripotent stem cells in drug and therapeutic development.

    (Oct 26, 2011)

    Electrophysiology of hiPSC-derived Cardiomyocytes

    From: The Podcast Series for AJP – Heart and Circulatory Physiology

    The discovery of induced pluripotent stem (iPS) cells has allowed researchers to generate human cardiomyocytes from patients. Why is this important? Human iPS cells are useful for studying normal and diseased human cardiomyocytes and for discovering new drug therapies to treat cardiovascular disease. Until now, methods for generating cardiomyocytes from human iPS or ES cells were inconsistent and often unreliable. The recent article by Ma et al presents a new method to obtain a large quantity of cultured cardiac myocytes using embryoid body formation and blasticidin selection techniques resulting in more than 98% purity from human iPS cell lines. Associate Editor Junichi Sadoshima talks with authors Craig January (University of Wisconsin – Madison) and Brad Swanson (Cellular Dynamics International), along with leading expert Diego Fraidenraich (University of Medicine and Dentistry, New Jersey), about this groundbreaking research and its many potential applications.

    View the Roche video, Arrhythmia Prediction Using iCell® Cardiomyocytes and the xCELLigence RTCA Cardio System

    Ion channel block is detected as irregular contractile activity in the hCAR Assay. iCell Cardiomyocytes were plated as a confluent monolayer and exposed to 0.03 mM of the hERG channel blocking agent, E-4031. The video shows the rhythmic contractile activity of the cardiomyocytes under control conditions (pre-drug) and the arrhythmic activity following drug application (E-4031 0.03 mM). Courtesy of Hoffmann-La Roche

    TKI-mediated Cardiotoxicity: iCell Cardiomyocytes as a Tool to Decipher Kinase Inhibitor Linked Toxicities

    Jennifer Cohen, Takeda California, Inc.
    Presented at the Cellular Dynamics Workshop at SOT 2012

    (May 13, 2012)

Still Have Questions?

If you did not find an answer to your question, please contact us to speak with an expert:

Business days: 8 AM - 4 PM ET